Canada markets close in 2 hours 14 minutes

AEON Biopharma, Inc. (AEON)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
1.7723-0.2177 (-10.94%)
As of 01:34PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close1.9900
Open1.9800
Bid1.7600 x 800
Ask1.7900 x 1200
Day's Range1.7700 - 1.9820
52 Week Range1.3800 - 17.1700
Volume66,334
Avg. Volume102,350
Market Cap69.336M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.4100
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
  • GlobeNewswire

    AEON Biopharma Reports First Quarter 2024 Financial Results

    – Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints – – Evaluating next-steps across the Company’s late-stage clinical pipeline for ABP-450 that targets multiple indications – IRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatmen

  • Zacks

    AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

    AEON Biopharma, Inc. (AEON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

  • GlobeNewswire

    AEON Biopharma Provides Update on Development Pipeline

    Includes two late-stage clinical programs and two early-stage clinical programsIRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today provided an update on the status of its late-stage clinical pipeline for ABP-450 that targets multiple indications. “In addition to our ear